|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||71.51 - 71.51|
|52-week range||22.00 - 90.35|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||23.65|
|Forward dividend & yield||1.45 (2.03%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||N/A|
Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.
A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.